Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $12 from $13 and keeps a Buy rating on the shares. The company’s Q1 results exceeded consensus estimates on all key metrics, with strong e-commerce sales offsetting lower sales to retail customers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE: